Abstract: A method for purification of a sulfatase using metal chelating chromatography without using tags such as His-tag, etc. is disclosed. An embodiment provides a method for purifying a sulfatase including the steps of: (a) providing a sulfatase-containing solution comprising one or a plurality of impurities; (b) performing a first chromatographic separation of the sulfatase-containing solution using a metal affinity chromatography resin; (c) performing a second chromatographic separation using a cation exchange chromatography resin; and (d) performing a final chromatographic separation using an anion exchange chromatography resin, wherein the impurities are removed thereby.

Abstract: A method for purification of a sulfatase using metal chelating chromatography without using tags such as His-tag, etc. is disclosed. An embodiment provides a method for purifying a sulfatase including the steps of: (a) providing a sulfatase-containing solution comprising one or a plurality of impurities; (b) performing a first chromatographic separation of the sulfatase-containing solution using a metal affinity chromatography resin; (c) performing a second chromatographic separation using a cation exchange chromatography resin; and (d) performing a final chromatographic separation using an anion exchange chromatography resin, wherein the impurities are removed thereby.

Abstract: A method for purifying fibrinogen includes steps of: (a) precipitating fibrinogen of a fibrinogen-containing solution by adding glycine to the solution for a concentration of glycine to be 1.5 to 2.5M, and then removing a supernatant and recovering a precipitate (1st glycine precipitation); (b) dissolving the precipitate of 1st glycine precipitation of step (a) in a dissolution buffer to obtain a solution, precipitating the solution by adding glycine thereto for a concentration of glycine to be 0.2 to 1.2M, and recovering a supernatant (2nd glycine precipitation); (c) precipitating the supernatant of step (b) by adding glycine thereto for a concentration of glycine to be 1.5 to 2.5M, and recovering a precipitate (3rd glycine precipitation); and (d) dissolving the precipitate of step (c) in a dissolution buffer to obtain a solution, and subjecting the solution to nanofiltration using a nanofilter.

Abstract: Provided are a kit for measuring a titer of a human antibody, a humanized antibody, or a human Fc-fusion protein in human plasma or serum, and a method for measuring a titer of a human Fc-containing protein in human plasma or serum using the same, and more specifically, a kit for measuring a titer of human Fc-containing protein in human plasma or serum, the kit including a diluent for sample, a diluent for conjugate, and a cleansing solution and being used in analysis through an indirect enzyme-linked immunosorbent assay (indirect ELISA), and a method for measuring a titer of human Fc-containing protein in human plasma or serum using the same.

Abstract: The present invention relates to a preparation method of a human plasma-derived hepatitis B immunoglobulin preparation. More specifically, the present invention relates to a preparation method of a human plasma-derived hepatitis B immunoglobulin preparation characterized in that plasma protein fraction II (fraction II) containing human hepatitis B immunoglobulin is dialysis concentrated and then thrombus-producing materials and impurities formed during processes are removed by anion exchange resin and cation exchange resin purification techniques. By using the preparation method of the human plasma-derived hepatitis B immunoglobulin preparation according to the present invention, the efficiency of removing impurities and thrombus-producing materials is increased and a polymer content is maintained, whereby it is possible to produce human hepatitis B immunoglobulin with stable and improved quality.

Abstract: A method for purifying fibrinogen includes steps of: (a) precipitating fibrinogen of a fibrinogen-containing solution by adding glycine to the solution for a concentration of glycine to be 1.5 to 2.5M, and then removing a supernatant and recovering a precipitate (1st glycine precipitation); (b) dissolving the precipitate of 1st glycine precipitation of step (a) in a dissolution buffer to obtain a solution, precipitating the solution by adding glycine thereto for a concentration of glycine to be 0.2 to 1.2M, and recovering a supernatant (2nd glycine precipitation); (c) precipitating the supernatant of step (b) by adding glycine thereto for a concentration of glycine to be 1.5 to 2.5M, and recovering a precipitate (3rd glycine precipitation); and (d) dissolving the precipitate of step (c) in a dissolution buffer to obtain a solution, and subjecting the solution to nanofiltration using a nanofilter.

Abstract: The present invention relates to a preparation method of a human plasma-derived hepatitis B immunoglobulin preparation. More specifically, the present invention relates to a preparation method of a human plasma-derived hepatitis B immunoglobulin preparation characterized in that plasma protein fraction II (fraction II) containing human hepatitis B immunoglobulin is dialysis concentrated and then thrombus-producing materials and impurities formed during processes are removed by anion exchange resin and cation exchange resin purification techniques. By using the preparation method of the human plasma-derived hepatitis B immunoglobulin preparation according to the present invention, the efficiency of removing impurities and thrombus-producing materials is increased and a polymer content is maintained, whereby it is possible to produce human hepatitis B immunoglobulin with stable and improved quality.

Abstract: Provided are a kit for measuring a titer of a human antibody, a humanized antibody, or a human Fc-fusion protein in human plasma or serum, and a method for measuring a titer of a human Fc-containing protein in human plasma or serum using the same, and more specifically, a kit for measuring a titer of human Fc-containing protein in human plasma or serum, the kit including a diluent for sample, a diluent for conjugate, and a cleansing solution and being used in analysis through an indirect enzyme-linked immunosorbent assay (indirect ELISA), and a method for measuring a titer of human Fc-containing protein in human plasma or serum using the same.

Abstract: A method and apparatus for suppressing vocoder noise are provided. In the method, first information and second information are received from a channel decoder, the first information indicating whether a decoded data frame has an error and the second information being a channel quality metric, error concealment voice decoding is performed on the decoded data frame if the first information indicates that no channel decoding error has been generated and the second information is smaller than a predetermined first threshold, and normal voice decoding is performed on the decoded data frame if the first information indicates that no channel decoding error has been generated and the second information is equal to or larger than the first threshold.

Abstract: A method and an apparatus for reducing noise due to a path change of an audio signal output from a device are provided. The method includes determining an input period for canceling the noise by using a time point, at which the path change is sensed, as a reference, when sensing the path change of the audio signal; low-pass filtering the audio signal in the determined input period; and interpolating a first partial signal, which is the low-pass filtered audio signal in a first predetermined period that starts from a start time point of the determined input period, and a second partial signal, which is the low-pass filtered audio signal in a second predetermined period that ends at an end time point of the determined input period, within the determined input period.

Abstract: Disclosed are an epitope specific to hepatitis B virus (HBV) and use thereof. The disclosed epitope is a conservative position on which mutagenesis does not occur and, therefore, a composition including an antibody to the foregoing epitope or a vaccine composition including the epitope has very low possibility of causing degradation of curing efficacy due to HBV mutation, thus being very useful for HBV treatment.

Abstract: Disclosed are an epitope specific to hepatitis B virus (HBV) and use thereof. The disclosed epitope is a conservative position on which mutagenesis does not occur and, therefore, a composition including an antibody to the foregoing epitope or a vaccine composition including the epitope has very low possibility of causing degradation of curing efficacy due to HBV mutation, thus being very useful for HBV treatment.

Abstract: An apparatus and a method for receiving a multiple frequency band are provided. In the method for receiving a multiple frequency band of a terminal is a mobile communication system, respective received signal strengths or respective gains are measured with respect to a signal received via at least one Radio Frequency (RF) chain. Whether multiple frequency band reception that uses a single RF chain is possible is determined using the respective received signal strengths or the respective gains. When the multiple frequency band reception that uses the single RF chain is possible, the multiple frequency band is received using the single RF chain.

Abstract: An apparatus and method for removing a Direct Current (DC) offset at a receiving terminal in a wireless communication system are provided. In the method, a frame is divided into at least two time resource blocks. Resource allocation information is used to discriminate between at least one time resource block of a data-unmapped interval and at least one time resource block of a data-mapped interval. The DC offset is measured during the data-unmapped interval. The DC offset is compensated during the data-unmapped interval on a time resource block basis by using the measured DC offset.

Abstract: A method and an apparatus for reducing noise due to a path change of an audio signal output from a device are provided. The method includes determining an input period for canceling the noise by using a time point, at which the path change is sensed, as a reference, when sensing the path change of the audio signal; low-pass filtering the audio signal in the determined input period; and interpolating a first partial signal, which is the low-pass filtered audio signal in a first predetermined period that starts from a start time point of the determined input period, and a second partial signal, which is the low-pass filtered audio signal in a second predetermined period that ends at an end time point of the determined input period, within the determined input period.

Abstract: Provided are antibodies specifically binding to the HBV surface antigen (HBsAg) which are effective for the prevention or treatment of hepatitis B.

Abstract: Provided are antibodies specifically binding to the HBV surface antigen (HBsAg) which are effective for the prevention or treatment of hepatitis B.

Abstract: Provided are antibodies specifically binding to the HBV surface antigen (HBsAg) which are effective for the prevention or treatment of hepatitis B.

Abstract: A method and apparatus for suppressing vocoder noise are provided. In the method, first information and second information are received from a channel decoder, the first information indicating whether a decoded data frame has an error and the second information being a channel quality metric, error concealment voice decoding is performed on the decoded data frame if the first information indicates that no channel decoding error has been generated and the second information is smaller than a predetermined first threshold, and normal voice decoding is performed on the decoded data frame if the first information indicates that no channel decoding error has been generated and the second information is equal to or larger than the first threshold.

Abstract: Provided are antibodies specifically binding to the epidermal growth factor receptor (EGFR) which are effective for the treatment of EGFR-mediated cancers.